Gregory M. Glenn

ORCID: 0000-0002-2030-8665

Publishes on SARS-CoV-2 and COVID-19 Research, biodegradable polymer synthesis and properties, Immunotherapy and Immune Responses. 281 papers and 19.1k citations.

PubIndex Score90Top 10% · seniorHow it's scored

281Publications

19.1kTotal Citations

First publication: 1955First senior author: 1995

SARS-CoV-2 and COVID-19 Research biodegradable polymer synthesis and properties Immunotherapy and Immune Responses Respiratory viral infections research Food composition and properties

Top publicationsby citations

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Mehreen S. Datoo, Halidou Tinto, Daniel Valia et al.|The Lancet|2021

Cited by 457

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Mehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|The Lancet Infectious Diseases|2022

Cited by 285

High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso

Mehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|SSRN Electronic Journal|2021

Cited by 15